Treatment of Relapsed or Refractory CD30 Positive Hodgkin and Non-Hodgkin Lymphomas Using CD30-Directed CAR T Cell Therapy CART30

What this Trial Is About

Researchers are evaluating the use of chimeric antigen receptor-modified T cells CART, specifically targeting CD30, for treating patients with relapsed or refractory CD30 positive Hodgkins lymphoma and Non-Hodgkins lymphoma. This trial aims to assess how these CART30 cells work in patients who have not responded to prior treatments or who cannot complete standard chemotherapy. The study is conducted in phases 1 and 2 to explore safety and treatment effects in this patient group. In this trial, patients first undergo a conditioning regimen with cyclophosphamide and fludarabine while their autologous CART30 cells are prepared from their own blood. One day after completing this regimen, patients receive infusions of the CART30 cells intravenously over 3 to 5 consecutive days with escalating doses. This approach allows the researchers to monitor how different doses of CART30 cells behave and their potential effects. Participants will have extra blood samples taken to measure how long the CART30 cells persist in the body. The main outcomes include tracking any adverse events related to the treatment up to 24 weeks and evaluating the anti-tumor response over the same period. The study includes continued monitoring to assess safety and treatment impact, with participation lasting through this observation timeframe.

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas